A review of Fabrys disease- pathophysiology, clinical presentation and treatments

Nusrat Aziz; Mamdouh Hasan Kalakatawi

doi:10.30574/gscbps.2021.14.1.0018

Authors

Nusrat Aziz Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, Kingdom of Saudi Arabia.
Mamdouh Hasan Kalakatawi Department of Neurology, Al Noor Specialists Hospital, Makkah, Kingdom of Saudi Arabia.

DOI:

https://doi.org/10.30574/gscbps.2021.14.1.0018

Keywords:

Fabrys disease, Pathophysiology, diagnosis, Treatment

Abstract

Fabrys disease is a lysosomal storage disorder, caused due to mutation in the GLA gene in X-chromosome encoding for alpha galactosidase A enzyme. It’s a pan ethnic disorder with multisystem involvement. The reported prevalence of Fabrys is less but new-born screening shows higher values, indicating it is largely underestimated.

It is inherited as X-linked dominant form. The hemizygous males manifests greater severity of symptoms and heterozygous females presents asymptomatic to severe symptoms. Pathophysiological changes occur due to insufficient breakdown of globotriosylceramide in lysosomes. Hence its accumulation causes dysfunction of cells, tissues and organ systems.

The classic type 1 of Fabrys disease shows symptoms in childhood and late-onset type 2 shows later in life at around 30-40 years of age. The early symptoms are neuropathic pain, diarrhea, corneal verticellata, hypohydrosis, intolerance to heat and exercise followed by renal, cardiac and cerebrovascular involvement. The life expectancy and quality of life in Fabrys disease is considerably lesser than of that of general population.

Rigorous new-born screening, detection in family members, early diagnosis and enzyme replacement and supportive management is important for slowing the progression of disease and decreases the morbidity and mortality, thus improving the overall well-being. There a is a need for awareness and education of physicians and patients about the disease with more research encouraged to develop newer and more efficient therapies for its management.

Metrics

Metrics Loading ...

References

Germain DP. Fabry disease. Orphanet J Rare Dis. 2010; 5: 30.

Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. Ann Saudi Med. 2010; 30(4): 271-277.

Alhemyadi SA, Elawad M, Fourtounas K, et al. Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia. Saudi Medical Journal. Aug 2020; 41(8): 813-818.

Colon C, Ortolano S, Melcon-Crespo C, Alvarez JV, Lopez-Suarez OE, Couce ML, Fernández-Lorenzo JR. Newborn screening for Fabry disease in the north-west of Spain. Eur J Pediatr. Aug 2017; 176(8): 1075-1081.

Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick R. High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*. The American Journal of Human Genetics. 2006; 79(1): 31-40.

Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Mastumoto S, Endo F, Hirose S, Nakamura K. Newborn screening for Fabry disease in the western region of Japan. Molecular genetics and metabolism reports. 2020; 22: 100562.

Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, Gal A, Beck M Eur J Pediatr. Nov 2003; 162(11): 767-72.

Mehta A, Hughes DA. Fabry Disease. [Updated 2017 Jan 5]. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. 5 Aug 2002; 1993-2021.

Bernardes T, Foresto R, Kirsztajn G. Fabry disease: genetics, pathology, and treatment. Revista da Associação Médica Brasileira. 2020; 66(suppl 1): s10-s16.

Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013; 19(33): 5974-5996.

S Baig, R Vijapurapu, F Alharbi, S Nordin, R Kozor, J Moon, B Bembi, T Geberhiwot, R P Steeds, Diagnosis and treatment of the cardiovascular consequences of Fabry disease, QJM: An International Journal of Medicine. January 2019; 112(1): 3–9.

Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Molecular Genetics and Metabolism. 2017; 122(3): 19-27.

Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010; 99(2): 99-108.

Hopkin R, Bissler J, Banikazemi M. et al. Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatr Res. 2008; 64: 550–555.

Crosbie TW, Packman W, Packman S. Psychological aspects of patients with Fabry disease. J. Inherit. Metab. Dis. 2009; 32: 745-753.

MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001; 38(11): 750-760.

Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM. et al. Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve. 2002; 26: 622–9.

Kuzman T, Juri J, Mrsić M, Jeren-Strujić B, Mandić Z, Sikić J. Fabryjeva bolest i promjene na ocima [Ocular findings in Fabry's disease]. Acta Med Croatica. 2006; 60(2): 163-166.

Libert J, Toussaint D. Tortuosities of retinal and conjunctival vessels in lysosomal storage diseases. Birth Defects Orig Artic Ser. 1982; 18: 347–58.

Hoffmann B, Schwarz M, Mehta A, Keshav S, Fabry Outcome Survey European Investigators. Clin Gastroenterol Hepatol. Dec 2007; 5(12): 1447-53.

Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M J Inherit Metab Dis. Apr 2007; 30(2): 184-92.

Larralde M, Boggio P, Amartino H, Chamoles N. Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol. 2004; 140: 1440–6.

Luna PC, Boggio P, Larralde M. Dermatologic aspects of Fabry disease. J Inborn Errors Metab Screen. 2016; 4: 1–7.

Germain D, Atanasiu OI, Akrout-Marouene J, Benistan K. Raynaud’s phenomenon associated with Fabry disease. J Inherit Metab Dis. 2015; 38: 367–8.

Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I. et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003; 162: 767–72.

Kokotis P, Üçeyler N, Werner C, Tsivgoulis G, Papanikola N, Katsanos A et al. Quantification of sweat gland innervation in patients with Fabry disease: A case-control study. Journal of the Neurological Sciences. 2018; 390: 135-138.

Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol. 1995; 12: 215–9.

Amann-Vesti BR, Gitzelmann G, Widmer U, Bosshard NU, Steinmann B, Koppensteiner R. Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol. 2003; 1: 185–9.

Sunder-Plassmann G. Renal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 21.

Torra R. Renal manifestations in Fabry disease and therapeutic options. Kidney International. 2008; 74: S29-S32.

Moiseev S, Fomin V, Savostyanov K, Pushkov A, Moiseev A, Svistunov A, Namazova-Baranova L: The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019; 141: 249-255.

Shanat Baig, Nicky C Edward, Dipak Kotecha, Boyang Liu, Sabrina Nordin, Rebecca Kozor, James C Moon, Tarekegn Geberhiwot, Richard P Steeds, Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice, EP Europace, Volume 20, Issue FI2. September 2018; f153–f161.

Schiffmann R, Moore DF. Neurological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 22.

Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol. 1996; 40: 8–17.

Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, et al.. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.J Neurol Neurosurg Psychiatry. 2008; 79: 1249–1254.

Ginsberg L. Chapter 23. Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey., Mehta A, Beck M, Sunder-Plassmann G, In: Fabry Disease: Perspectives From 5 Years of FOS. Oxford: Oxford PharmaGenesis. 2006.

Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med. Genet. 2002; 3: 10.

Faggiano A, Pisani A, Milone F, et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab. 2006; 91(11): 4319-4325.

Mersebach H, Johansson JO, Rasmussen å. et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med. 2007; 9: 812–818.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JTR, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet. Med. 2013; 15: 983-989.

Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M et al. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clinical Kidney Journal. 2020.

C Tøndel, L Bostad, KK Larsen, et al.Agalsidase benefits renal histology in young patients with Fabry disease J. Am. Soc. Nephrol. 2003; 24: 137-148.

F Weidemann, M Niemann, S Störk, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications J. Intern. Med. 2013; 274: 331-341.

Müntze J, Gensler D, Maniuc O, et al. Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year. Clin Pharmacol Ther. 2019; 105(5): 1224-1233. Riccio E, Zanfardino M, Ferreri L. et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020; 28: 1662–1668.

Zar-Kessler C, Karaa A, Sims KB, Clarke V, Kuo B. Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Therap Adv Gastroenterol. 2016; 9(4): 626-634.

Walker M. Experimental Treatments for Fabry Disease [Internet]. Fabry Disease News. 2021.

Waldek S, Patel M, Banikazemi M. et al. Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genet Med. 2009; 11; 790–796.